Actemra Looks Promising in Scleroderma
Encouraging results were seen for tocilizumab (Actemra) in the treatment of diffuse systemic sclerosis (SSc) in a proof-of-concept study by Christopher P. Denton, MBBS, of University College Londo.
At 24 weeks, a numerically favorable response was seen on modified Rodnan skin scores and lung fibrosis among patients randomized to tocilizumab compared with those receiving placebo. The study is now continuing with a phase III trial that includes a greater number of patients.
news & events
PRESS RELEASE: European associations align in the battle against systemic sclerosis for World Scleroderma Day 2019
We are happy to share with you the latest newsletter from FESCA.
The juvenile scleroderma inceptions project has the aim to learn more about juvenile Systemic Sclerosis.